Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001610717-25-000359
Filing Date
2025-10-06
Accepted
2025-10-06 16:32:29
Documents
2
Period of Report
2025-10-02

Document Format Files

Seq Description Document Type Size
1 form3.html 3  
1 form3.xml 3 1448
2 POWER OF ATTORNEY poamoore.htm EX-24.1 7211
  Complete submission text file 0001610717-25-000359.txt   10128
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Issuer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O CORVUS PHARMACEUTICALS, INC. 901 GATEWAY BOULEVARD, THIRD FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
Moore David Scott (Reporting) CIK: 0002088466 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37719 | Film No.: 251377201